Medical Xpress
MAY 16, 2023
That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.
The Pharma Data
NOVEMBER 5, 2020
Drawing upon 50 years of expertise in clinical research, biopharmaceuticals, biotechnology and drug discovery, Dr. Van Kampen excels as the chief executive officer of The Van Kampen Group, which assists other companies in research and liaisons with government and industry regarding licensing products for commercial use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 6, 2022
So, when a new disease emerges, researchers have a near-impossible task working upstream from symptoms to identify the underlying cause and biological mechanisms causing disease. This problem is compounded when researchers are presented with a complex set of symptoms, with no easily identifiable infectious agent as the cause.
pharmaphorum
JANUARY 29, 2021
This has, of course, garnered immense excitement – Doctors Emmanuelle Charpentier and Jennifer Doudna were named winners of the Nobel Prize for chemistry in recognition of their discovery of CRISPR/Cas9 gene editing technology. Zinc fingers. Macrae had previously worked at GSK and Takeda before he was recruited by Sangamo.
Drug Discovery World
APRIL 3, 2023
DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD. What advantages do they offer over antibodies?  
The Pharma Data
JANUARY 4, 2021
Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. Barber is an associate professor of biology and director of the Office of Student Research. “We believe Prof. About PD-1 Check-point inhibition.
Drug Discovery World
FEBRUARY 15, 2023
The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. This is an exciting field of cancer research which involves harnessing the body’s own immune system to target cancerous cells. This continues to be the standard of care.
Expert insights. Personalized for you.
98 
Let's personalize your content